Third Department of Surgery, Attikon University Hospital, National and Kapodistrian University of Athens Medical School, Athens, Greece.
Department of Surgery, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
Ann Surg Oncol. 2024 Mar;31(3):1823-1832. doi: 10.1245/s10434-023-14774-9. Epub 2023 Dec 28.
Although some data suggest that patients with mutRAS colorectal liver metastases (CRLM) may benefit from anatomic hepatectomy, this topic remains controversial. We performed a systematic review and meta-analysis to determine whether RAS mutation status was associated with prognosis relative to surgical technique [anatomic resection (AR) vs. nonanatomic resection (NAR)] among patients with CRLM.
A systematic review and meta-analysis of studies were performed to investigate the association of AR versus NAR with overall and liver-specific disease-free survival (DFS and liver-specific DFS, respectively) in the context of RAS mutation status.
Overall, 2018 patients (831 mutRAS vs. 1187 wtRAS) were included from five eligible studies. AR was associated with a 40% improvement in liver-specific DFS [hazard ratio (HR) = 0.6, 95% confidence interval (CI) 0.44-0.81, p = 0.01] and a 28% improvement in overall DFS (HR = 0.72, 95% CI 0.54-0.95, p = 0.02) among patients with mutRAS tumors; in contrast, AR was not associated with any improvement in liver-specific DFS or overall DFS among wtRAS patients. These differences may have been mediated by the 40% decreased incidence in R1 resection among patients with mutRAS tumors who underwent AR versus NAR [relative risk (RR): 0.6, 95% CI 0.40-0.91, p = 0.02]. In contrast, the probability of an R1 resection was not decreased among wtRAS patients who underwent AR versus NAR (RR: 0.93, 95% CI 0.69-1.25, p = 0.62).
The data suggest that precision surgery may be relevant to CRLM. Specifically, rather than a parenchymal sparing dogma for all patients, AR may have a role in individuals with mutRAS tumors.
尽管一些数据表明,具有 mutRAS 结直肠癌肝转移(CRLM)的患者可能从解剖性肝切除术获益,但这一主题仍存在争议。我们进行了系统评价和荟萃分析,以确定 RAS 突变状态与 CRLM 患者手术技术(解剖性切除术(AR)与非解剖性切除术(NAR))相关的预后之间是否存在关联。
系统评价和荟萃分析研究调查了 RAS 突变状态背景下,AR 与 NAR 与总体和肝脏特异性无病生存(DFS 和肝脏特异性 DFS,分别)的关联。
共有 5 项符合条件的研究纳入了 2018 例患者(831 例 mutRAS 与 1187 例 wtRAS)。在 mutRAS 肿瘤患者中,AR 与肝脏特异性 DFS 改善 40%相关[风险比(HR)=0.6,95%置信区间(CI)0.44-0.81,p=0.01],与总体 DFS 改善 28%相关(HR=0.72,95%CI 0.54-0.95,p=0.02);相比之下,AR 与 wtRAS 患者的肝脏特异性 DFS 或总体 DFS 改善无关。在 mutRAS 肿瘤患者中,AR 与 NAR 相比,R1 切除的发生率降低了 40%,这可能介导了这些差异[相对风险(RR):0.6,95%CI 0.40-0.91,p=0.02]。相比之下,在 wtRAS 患者中,AR 与 NAR 相比,R1 切除的概率并未降低(RR:0.93,95%CI 0.69-1.25,p=0.62)。
数据表明,精准手术可能与 CRLM 相关。具体来说,AR 可能在 mutRAS 肿瘤患者中发挥作用,而不是所有患者的保留实质的教条。